Vivani Medical Inc. (VANI) Stock Forecast & Price Target
Vivani Medical Inc. · NASDAQ
$1.30+0.02 (+1.56%)
15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Vivani Medical Inc, 2 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $3.50 to $4.00, so the covering firms are broadly aligned. The average target of $3.75 sits 188% above the current $1.30. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 1 to 2 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.08 next quarter toward $-0.44 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Moderate Buy
Strong Buy00%
Buy2100%
Hold00%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Vivani Medical Inc.
As of Jul, 2 of 2 firms rate VANI a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
VANI EPS & revenue forecast
EPS · NEXT QUARTER
$-0.08
Range $-0.09 – $-0.07 · 3 analysts · -24% YoY
Next period, 3 analysts expect Vivani Medical Inc. to earn $-0.08 a share (range $-0.09 – $-0.07), versus $-0.11 a year earlier. Full-year consensus is $-0.34, growing to $-0.44 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 3 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Vivani Medical Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on VANI.
#1
Yi Chen
HC Wainwright & Co. · Rank #238
Buy
$3.50+169.2% to target
Overall win rate
34%
+ Follow
#2
TF
Thomas Flaten
Lake Street
Buy
$4.00+207.7% to target
Coverage
—
+ Follow
VANI stock forecast FAQ
What is VANI's average 12-month price target?+
The 2 analysts with a live target average $3.75 for Vivani Medical Inc. over the next 12 months, ranging from a $4.00 high to a $3.50 low.
Is VANI stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 2 analyst ratings, 2 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for VANI?+
The Street-high target is $4.00 (Lake Street), and the Street-low is $3.50 (HC Wainwright & Co.). The average of all 2 active targets is $3.75.
How many Wall Street analysts cover VANI?+
2 analysts have an active rating on Vivani Medical Inc., and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering VANI?+
Among analysts who currently cover VANI, Yi Chen of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #238). Their current call is Buy with a $3.50 target.
What is Vivani Medical Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.08 per share (range $-0.09 – $-0.07) across 3 analysts. Full-year EPS is projected at $-0.34, rising to $-0.44 the following year.
How much revenue is Vivani Medical Inc. expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading VANI lately?+
As of Jul, 2 of 2 firms rate VANI a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their VANI calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
